Metagenomi Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Metagenomi Therapeutics (MGX).

Price Target Range — 9 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$10Upside to Avg. PT+1208.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 11, 2026	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$9→$7
Jul 7, 2026	Chardan Capital	Keay Nakae	PT Cut	Buy	$7→$5
May 12, 2026	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$12→$9
Aug 19, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$7
Aug 15, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$12→$11
Aug 14, 2025	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$16→$12
May 15, 2025	Chardan Capital	Geulah Livshits	PT Cut	Buy	$13→$12
May 14, 2025	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$20→$16
Apr 3, 2025	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Buy	$14→$7
Mar 18, 2025	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$25→$20
Dec 10, 2024	HC Wainwright & Co.	Mitchell Kapoor	PT Raise	Buy	$7→$14
Nov 21, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$7
Nov 20, 2024	Chardan Capital	Geulah Livshits	Maintained	Buy	$15
Oct 15, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$7
Sep 6, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$7
Sep 5, 2024	Chardan Capital	Geulah Livshits	Maintained	Buy	$15
Aug 21, 2024	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Buy	$10→$7
Aug 19, 2024	Chardan Capital	Geulah Livshits	PT Cut	Buy	$17→$15
Aug 15, 2024	BMO Capital	Kostas Biliouris	PT Cut	Outperform	$22→$17
Jul 15, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$10

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7

Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $9 to $7.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5

Chardan Capital analyst Keay Nakae maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Buy and lowers the price target from $7 to $5.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $9

Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $12 to $9.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Metagenomi (NASDAQ:MGX) with a Buy and maintains $7 price target.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $11

Chardan Capital analyst Geulah Livshits maintains Metagenomi (NASDAQ:MGX) with a Buy and lowers the price target from $12 to $11.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $12

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:MGX) with a Overweight and lowers the price target from $16 to $12.

Benzinga Newsdesk

Metagenomi Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Metagenomi Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7

PRO
Chardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5

PRO
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $9

PRO
HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target

PRO
Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $11

PRO
Wells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $12

People Also Watch

People Also Watch

Metagenomi Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Metagenomi Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7

PROChardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5

PROWells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $9

PROHC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target

PROChardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $11

PROWells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $12

People Also Watch

People Also Watch

PRO
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7

PRO
Chardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5

PRO
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $9

PRO
HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target

PRO
Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $11

PRO
Wells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $12